Kirby McInerney | <span >NextCure, Inc.</span >
This links to the home page

NextCure, Inc.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of those who acquired NextCure, Inc. (“NextCure” or the “Company”) (NASDAQ: NXTC) securities during the period from November 5, 2019 through July 14, 2020, inclusive (the “Class Period”). Investors have until November 20, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the Complaint, the Company made false and misleading statements to the market. NextCure made numerous misleading statements about its treatment candidate, NC318. The Company misled the market on NC318’s effectiveness and patient responses to the candidate, among other things. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about NextCure, investors suffered damages.
If you acquired NextCure securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.  

NextCure, Inc. Investor Contact Form